Martha L. Daviglus
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Martha L. Daviglus has a total of 81 co-authors. Here are the top co-authors by number of shared publications:
- Amber Pirzada
University of Illinois at Chicago
13 shared publications Philip Greenland
From the Department of Preventive Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL;1 the Department of Cardiology, Wayne State University, Detroit, MI;2 and the Department of Health Economics and Management, Guanghua School of Management, Peking University, Beijing, China3
10 shared publicationsJeremiah Stamler
9 shared publicationsLijing L. Yan
From the Department of Preventive Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL;1 the Department of Cardiology, Wayne State University, Detroit, MI;2 and the Department of Health Economics and Management, Guanghua School of Management, Peking University, Beijing, China3
9 shared publicationsAlan R. Dyer
From the Department of Preventive Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL;1 the Department of Cardiology, Wayne State University, Detroit, MI;2 and the Department of Health Economics and Management, Guanghua School of Management, Peking University, Beijing, China3
8 shared publicationsDaniel B. Garside
8 shared publications
Latest Publications
- Open Access
- 14 May 2013
- Published by Springer Nature in BMC Public Health
- Vol. 13 (1) , 468
Self-perceived physical health predicts cardiovascular disease incidence and death among postmenopausal women
Physical and Mental Component Summary (PCS, MCS, respectively) scales of SF- 36 health-related-quality-of-life have been associated with all-cause and cardiovascular disease (CVD) mortality. Their relationships with CVD incidence are unclear. This study purpose was to test whether PCS and/or MCS were associated with CVD incidence and death. Postmenopausal women (aged 50–79 years) in control groups of the Women’s Health Initiative clinical trials (n = 20,308) completed the SF-36 and standardized questionnaires at trial entry. Health outcomes, assessed semi-annually, were verified with medical records. Cox regressions assessed time to selected outcomes during the trial phase (1993–2005). A total of 1075 incident CVD events, 204 CVD-specific deaths, and 1043 total deaths occurred during the trial phase. Women with low versus high baseline PCS scores had less favorable health profiles at baseline. In multivariable models adjusting for baseline confounders, participants in the lowest PCS quintile (reference = highest quintile) exhibited 1.8 (95%CI: 1.4, 2.3), 4.7 (95%CI: 2.3, 9.4), and 2.1 (95%CI: 1.7, 2.7) times greater risk of CVD incidence, CVD-specific death, and total mortality, respectively, by trial end; whereas, MCS was not significantly associated with CVD incidence or death. Physical health, assessed by self-report of physical functioning, is a strong predictor of CVD incidence and death in postmenopausal women; similar self-assessment of mental health is not. PCS should be evaluated as a screening tool to identify older women at high risk for CVD development and death.
- 14 May 2013
- Published by Springer Nature in BMC Public Health
- Vol. 13 (1) , 468
Open AccessSelf-perceived physical health predicts cardiovascular disease incidence and death among postmenopausal women
Physical and Mental Component Summary (PCS, MCS, respectively) scales of SF- 36 health-related-quality-of-life have been associated with all-cause and cardiovascular disease (CVD) mortality. Their relationships with CVD incidence are unclear. This study purpose was to test whether PCS and/or MCS were associated with CVD incidence and death. Postmenopausal women (aged 50–79 years) in control groups of the Women’s Health Initiative clinical trials (n = 20,308) completed the SF-36 and standardized questionnaires at trial entry. Health outcomes, assessed semi-annually, were verified with medical records. Cox regressions assessed time to selected outcomes during the trial phase (1993–2005). A total of 1075 incident CVD events, 204 CVD-specific deaths, and 1043 total deaths occurred during the trial phase. Women with low versus high baseline PCS scores had less favorable health profiles at baseline. In multivariable models adjusting for baseline confounders, participants in the lowest PCS quintile (reference = highest quintile) exhibited 1.8 (95%CI: 1.4, 2.3), 4.7 (95%CI: 2.3, 9.4), and 2.1 (95%CI: 1.7, 2.7) times greater risk of CVD incidence, CVD-specific death, and total mortality, respectively, by trial end; whereas, MCS was not significantly associated with CVD incidence or death. Physical health, assessed by self-report of physical functioning, is a strong predictor of CVD incidence and death in postmenopausal women; similar self-assessment of mental health is not. PCS should be evaluated as a screening tool to identify older women at high risk for CVD development and death.
- Open Access
Diet Composition and Activity Level of at Risk and Metabolically Healthy Obese American Adults
- 1 September 2011
- Published by American Medical Association (AMA) in Archives of Neurology
- Vol. 68 (9) , 1185-1190
Risk Factors and Preventive Interventions for Alzheimer Disease
Background: Numerous studies have investigated risk factors for Alzheimer disease (AD). However, at a recent National Institutes of Health State-of-the-Science Conference, an independent panel found insufficient evidence to support the association of any modifiable factor with risk of cognitive decline or AD.Objective: To present key findings for selected factors and AD risk that led the panel to their conclusion.Data Sources: An evidence report was commissioned by the Agency for Healthcare Research and Quality. It included English-language publications in MEDLINE and the Cochrane Database of Systematic Reviews from 1984 through October 27, 2009. Expert presentations and public discussions were considered.Study Selection: Study inclusion criteria for the evidence report were participants aged 50 years and older from general populations in developed countries; minimum sample sizes of 300 for cohort studies and 50 for randomized controlled trials; at least 2 years between exposure and outcome assessment; and use of well-accepted diagnostic criteria for AD.Data Extraction: Included studies were evaluated for eligibility and data were abstracted. Quality of overall evidence for each factor was summarized as low, moderate, or high.Data Synthesis: Diabetes mellitus, hyperlipidemia in midlife, and current tobacco use were associated with increased risk of AD, and Mediterranean-type diet, folic acid intake, low or moderate alcohol intake, cognitive activities, and physical activity were associated with decreased risk. The quality of evidence was low for all of these associations.Conclusion: Currently, insufficient evidence exists to draw firm conclusions on the association of any modifiable factors with risk of AD.
- 1 September 2011
- Published by American Medical Association (AMA) in Archives of Neurology
- Vol. 68 (9) , 1185-1190
Risk Factors and Preventive Interventions for Alzheimer Disease
Background: Numerous studies have investigated risk factors for Alzheimer disease (AD). However, at a recent National Institutes of Health State-of-the-Science Conference, an independent panel found insufficient evidence to support the association of any modifiable factor with risk of cognitive decline or AD.Objective: To present key findings for selected factors and AD risk that led the panel to their conclusion.Data Sources: An evidence report was commissioned by the Agency for Healthcare Research and Quality. It included English-language publications in MEDLINE and the Cochrane Database of Systematic Reviews from 1984 through October 27, 2009. Expert presentations and public discussions were considered.Study Selection: Study inclusion criteria for the evidence report were participants aged 50 years and older from general populations in developed countries; minimum sample sizes of 300 for cohort studies and 50 for randomized controlled trials; at least 2 years between exposure and outcome assessment; and use of well-accepted diagnostic criteria for AD.Data Extraction: Included studies were evaluated for eligibility and data were abstracted. Quality of overall evidence for each factor was summarized as low, moderate, or high.Data Synthesis: Diabetes mellitus, hyperlipidemia in midlife, and current tobacco use were associated with increased risk of AD, and Mediterranean-type diet, folic acid intake, low or moderate alcohol intake, cognitive activities, and physical activity were associated with decreased risk. The quality of evidence was low for all of these associations.Conclusion: Currently, insufficient evidence exists to draw firm conclusions on the association of any modifiable factors with risk of AD.
- 28 April 2010
- Vol. 27 (4) , 1-30
NIH state-of-the-science conference statement: Preventing Alzheimer's disease and cognitive decline.
To provide health care providers, patients, and the general public with a responsible assessment of currently available data on prevention of Alzheimer's disease and cognitive decline. A non-Department of Health and Human Services, nonadvocate 15-member panel representing the fields of preventive medicine, geriatrics, internal medicine, neurology, neurological surgery, psychiatry, mental health, human nutrition, pharmacology, genetic medicine, nursing, health economics, health services research, family caregiving, and a public representative. In addition, 20 experts from pertinent fields presented data to the panel and conference audience. Presentations by experts and a systematic review of the literature prepared by the Duke University Evidence-based Practice Center, through the Agency for Healthcare Research and Quality. Scientific evidence was given precedence over anecdotal experience. The panel drafted its statement based on scientific evidence presented in open forum and on published scientific literature. The draft statement was presented on the final day of the conference and circulated to the audience for comment. The panel released a revised statement later that day at http://consensus.nih.gov. This statement is an independent report of the panel and is not a policy statement of the NIH or the Federal Government. Cognitive decline and Alzheimer’s disease are major causes of morbidity and mortality worldwide and are substantially burdensome to the affected persons, their caregivers, and society in general. Extensive research over the past 20 years has provided important insights on the nature of Alzheimer’s disease and cognitive decline and the magnitude of the problem. Nevertheless, there remain important and formidable challenges in conducting research on these diseases, particularly in the area of prevention. Currently, firm conclusions cannot be drawn about the association of any modifiable risk factor with cognitive decline or Alzheimer’s disease. Highly reliable consensus-based diagnostic criteria for cognitive decline, mild cognitive impairment, and Alzheimer’s disease are lacking, and available criteria have not been uniformly applied. Evidence is insufficient to support the use of pharmaceutical agents or dietary supplements to prevent cognitive decline or Alzheimer’s disease. We recognize that a large amount of promising research is under way; these efforts need to be increased and added to by new understandings and innovations (as noted in our recommendations for future research). For example, ongoing studies including (but not limited to) studies on antihypertensive medications, omega-3 fatty acids, physical activity, and cognitive engagement may provide new insights into the prevention or delay of cognitive decline or Alzheimer’s disease. This important research needs to be supplemented by further studies. Large-scale population-based studies and randomized controlled trials (RCTs) are critically needed to investigate strategies to maintain cognitive function in individuals at risk for decline, to identify factors that may delay the onset of Alzheimer’s disease among persons at risk, and to identify factors that may slow the progression of Alzheimer’s disease among persons in whom the condition is already diagnosed.
- 28 April 2010
- Vol. 27 (4) , 1-30
NIH state-of-the-science conference statement: Preventing Alzheimer's disease and cognitive decline.
To provide health care providers, patients, and the general public with a responsible assessment of currently available data on prevention of Alzheimer's disease and cognitive decline. A non-Department of Health and Human Services, nonadvocate 15-member panel representing the fields of preventive medicine, geriatrics, internal medicine, neurology, neurological surgery, psychiatry, mental health, human nutrition, pharmacology, genetic medicine, nursing, health economics, health services research, family caregiving, and a public representative. In addition, 20 experts from pertinent fields presented data to the panel and conference audience. Presentations by experts and a systematic review of the literature prepared by the Duke University Evidence-based Practice Center, through the Agency for Healthcare Research and Quality. Scientific evidence was given precedence over anecdotal experience. The panel drafted its statement based on scientific evidence presented in open forum and on published scientific literature. The draft statement was presented on the final day of the conference and circulated to the audience for comment. The panel released a revised statement later that day at http://consensus.nih.gov. This statement is an independent report of the panel and is not a policy statement of the NIH or the Federal Government. Cognitive decline and Alzheimer’s disease are major causes of morbidity and mortality worldwide and are substantially burdensome to the affected persons, their caregivers, and society in general. Extensive research over the past 20 years has provided important insights on the nature of Alzheimer’s disease and cognitive decline and the magnitude of the problem. Nevertheless, there remain important and formidable challenges in conducting research on these diseases, particularly in the area of prevention. Currently, firm conclusions cannot be drawn about the association of any modifiable risk factor with cognitive decline or Alzheimer’s disease. Highly reliable consensus-based diagnostic criteria for cognitive decline, mild cognitive impairment, and Alzheimer’s disease are lacking, and available criteria have not been uniformly applied. Evidence is insufficient to support the use of pharmaceutical agents or dietary supplements to prevent cognitive decline or Alzheimer’s disease. We recognize that a large amount of promising research is under way; these efforts need to be increased and added to by new understandings and innovations (as noted in our recommendations for future research). For example, ongoing studies including (but not limited to) studies on antihypertensive medications, omega-3 fatty acids, physical activity, and cognitive engagement may provide new insights into the prevention or delay of cognitive decline or Alzheimer’s disease. This important research needs to be supplemented by further studies. Large-scale population-based studies and randomized controlled trials (RCTs) are critically needed to investigate strategies to maintain cognitive function in individuals at risk for decline, to identify factors that may delay the onset of Alzheimer’s disease among persons at risk, and to identify factors that may slow the progression of Alzheimer’s disease among persons in whom the condition is already diagnosed.
- Open Access
- 20 October 2008
- Published by Wiley in Preventive Cardiology
- Vol. 11 (3) , 141-147
Relation of heart rate with cardiovascular disease in normal-weight individuals: the Chicago Heart Association Detection Project in Industry.
- 20 October 2008
- Published by Wiley in Preventive Cardiology
- Vol. 11 (3) , 141-147
Open AccessRelation of heart rate with cardiovascular disease in normal-weight individuals: the Chicago Heart Association Detection Project in Industry.
- 1 January 2006
- Published by Springer Nature in American Journal of Cardiovascular Drugs
- Vol. 6 (2) , 87-101
Preventing Cardiovascular Disease in the 21st Century
Cardiovascular disease (CVD), particularly coronary heart disease (CHD), remains a major cause of mortality, morbidity, and disability in the US and other Westernized societies. As a result of therapeutic and preventive measures to control the CVD/CHD epidemic, mortality has declined steadily during the last several decades with a consequent gain in life expectancy, but the 1990s witnessed a slowing of this decline. In response to these trends, a range of therapeutic regimens were developed to address adverse CVD risk factor levels and their deleterious effects. The scientific evidence regarding the efficacy, cost effectiveness, strengths, and limitations of a range of pharmacologic and lifestyle approaches to CVD prevention — both primary and secondary — are reviewed in depth. Clinical trials aimed at primary and secondary prevention of CVD have documented the efficacy and cost effectiveness of various drugs in lowering individual risk factor levels and in reducing clinical CVD events. More recently, the idea of a ‘polypill’ containing low doses of multiple drugs has generated much interest, with proponents arguing that, given the high prevalence of CVD risk factors and the effectiveness of pharmacologic interventions, such a drug combination would reduce CHD mortality by 88% if taken by all individuals aged α55 years. However, current treatments to control high BP and serum cholesterol, while effective, do not typically reduce morbidity and mortality to levels observed in low-risk individuals, i.e. those with favorable levels of all readily measured major risk factors. Rather, primary prevention of all major risk factors starting early in life is critical. Prospective population-based research has delineated multiple long-term benefits associated with low-risk status in young adulthood and middle age, i.e. markedly lower age-specific CVD and total mortality rates, increased life expectancy, lower healthcare costs, lower medication use and prevalence of chronic diseases, and higher self-reported quality of life at older ages. Unfortunately, despite declines in the prevalence of most major CVD risk factors, low-risk status remains rare among US adults. Data have also demonstrated that adverse levels of one or more major risk factors precede clinical CHD in 90% or more of all cases, undermining the assertion that major CVD risk factors account for ‘no more than 50%’ of CHD cases. Hence, while numerous treatment options exist for secondary prevention of CVD, strategies that focus on progressively increasing the proportion of low-risk individuals could greatly reduce the need for secondary prevention in the first place. Public health policies must focus on prevention of all major risk factors simultaneously, using lifestyle approaches from early ages onwards to reduce population CVD risk to endemic levels, rather than current epidemic levels.
- 1 January 2006
- Published by Springer Nature in American Journal of Cardiovascular Drugs
- Vol. 6 (2) , 87-101
Preventing Cardiovascular Disease in the 21st Century
Cardiovascular disease (CVD), particularly coronary heart disease (CHD), remains a major cause of mortality, morbidity, and disability in the US and other Westernized societies. As a result of therapeutic and preventive measures to control the CVD/CHD epidemic, mortality has declined steadily during the last several decades with a consequent gain in life expectancy, but the 1990s witnessed a slowing of this decline. In response to these trends, a range of therapeutic regimens were developed to address adverse CVD risk factor levels and their deleterious effects. The scientific evidence regarding the efficacy, cost effectiveness, strengths, and limitations of a range of pharmacologic and lifestyle approaches to CVD prevention — both primary and secondary — are reviewed in depth. Clinical trials aimed at primary and secondary prevention of CVD have documented the efficacy and cost effectiveness of various drugs in lowering individual risk factor levels and in reducing clinical CVD events. More recently, the idea of a ‘polypill’ containing low doses of multiple drugs has generated much interest, with proponents arguing that, given the high prevalence of CVD risk factors and the effectiveness of pharmacologic interventions, such a drug combination would reduce CHD mortality by 88% if taken by all individuals aged α55 years. However, current treatments to control high BP and serum cholesterol, while effective, do not typically reduce morbidity and mortality to levels observed in low-risk individuals, i.e. those with favorable levels of all readily measured major risk factors. Rather, primary prevention of all major risk factors starting early in life is critical. Prospective population-based research has delineated multiple long-term benefits associated with low-risk status in young adulthood and middle age, i.e. markedly lower age-specific CVD and total mortality rates, increased life expectancy, lower healthcare costs, lower medication use and prevalence of chronic diseases, and higher self-reported quality of life at older ages. Unfortunately, despite declines in the prevalence of most major CVD risk factors, low-risk status remains rare among US adults. Data have also demonstrated that adverse levels of one or more major risk factors precede clinical CHD in 90% or more of all cases, undermining the assertion that major CVD risk factors account for ‘no more than 50%’ of CHD cases. Hence, while numerous treatment options exist for secondary prevention of CVD, strategies that focus on progressively increasing the proportion of low-risk individuals could greatly reduce the need for secondary prevention in the first place. Public health policies must focus on prevention of all major risk factors simultaneously, using lifestyle approaches from early ages onwards to reduce population CVD risk to endemic levels, rather than current epidemic levels.
- 1 November 2005
- Published by Elsevier in Journal of the American Dietetic Association
- Vol. 105 (11) , 1735-1744
Relationship of Fruit and Vegetable Consumption in Middle-Aged Men to Medicare Expenditures in Older Age: The Chicago Western Electric Study
- 1 November 2005
- Published by Elsevier in Journal of the American Dietetic Association
- Vol. 105 (11) , 1735-1744
Relationship of Fruit and Vegetable Consumption in Middle-Aged Men to Medicare Expenditures in Older Age: The Chicago Western Electric Study
- 9 May 2005
- Published by American Medical Association (AMA) in Archives of internal medicine (1960)
- Vol. 165 (9) , 1028-1034
Cardiovascular Risk Profile Earlier in Life and Medicare Costs in the Last Year of Life
Research from JAMA Internal Medicine — Cardiovascular Risk Profile Earlier in Life and Medicare Costs in the Last Year of Life
- 9 May 2005
- Published by American Medical Association (AMA) in Archives of internal medicine (1960)
- Vol. 165 (9) , 1028-1034
Cardiovascular Risk Profile Earlier in Life and Medicare Costs in the Last Year of Life
Research from JAMA Internal Medicine — Cardiovascular Risk Profile Earlier in Life and Medicare Costs in the Last Year of Life
- 1 April 2005
- Published by Taylor & Francis in Expert Review of Pharmacoeconomics & Outcomes Research
- Vol. 5 (2) , 125-130
In the long run, healthcare costs appear to be related to overweight and obesity at younger ages
Overweight and obesity are associated with a higher risk of cardiovascular disease and noncardiovascular disease morbidity and mortality, and shorter life expectancy. Despite declines in prevalence of other key major cardiovascular disease risk factors, the prevalence of overweight and obesity has reached epidemic proportions and it continues to rise. This has implications for future Medicare expenditures. Recent findings indicate that irrespective of interim changes in weight, being overweight or obese in young adulthood and middle age is significantly and positively associated with higher average annual and cumulative cardiovascular disease-related and total Medicare charges in older age. However, the prevention and control of overweight and obesity has proven difficult due to overconsumption of calorie-dense foods, sedentary lifestyles, and insufficient and ineffective treatment options. Clinicians should emphasize weight management strategies for all patients and public health authorities should implement policies that promote maintenance and achievement of healthy weight through systemic environmental changes. Emphasis on the primary prevention of weight gain from early life onwards by adoption of healthy lifestyles, and prevention and control of excess weight at all ages are urgently required to contain and end the obesity epidemic and to reduce healthcare costs incurred by older people.
- 1 April 2005
- Published by Taylor & Francis in Expert Review of Pharmacoeconomics & Outcomes Research
- Vol. 5 (2) , 125-130
In the long run, healthcare costs appear to be related to overweight and obesity at younger ages
Overweight and obesity are associated with a higher risk of cardiovascular disease and noncardiovascular disease morbidity and mortality, and shorter life expectancy. Despite declines in prevalence of other key major cardiovascular disease risk factors, the prevalence of overweight and obesity has reached epidemic proportions and it continues to rise. This has implications for future Medicare expenditures. Recent findings indicate that irrespective of interim changes in weight, being overweight or obese in young adulthood and middle age is significantly and positively associated with higher average annual and cumulative cardiovascular disease-related and total Medicare charges in older age. However, the prevention and control of overweight and obesity has proven difficult due to overconsumption of calorie-dense foods, sedentary lifestyles, and insufficient and ineffective treatment options. Clinicians should emphasize weight management strategies for all patients and public health authorities should implement policies that promote maintenance and achievement of healthy weight through systemic environmental changes. Emphasis on the primary prevention of weight gain from early life onwards by adoption of healthy lifestyles, and prevention and control of excess weight at all ages are urgently required to contain and end the obesity epidemic and to reduce healthcare costs incurred by older people.